In the aqueous humor of diabetics with DME, increased level of the vascular endothelial growth factor (VEGF)—a significant blood–retinal barrier breakdown mediator—was observed, which led to the hypothesis that alternative or adjunct therapies using VEGF inhibitors could be beneficial in reversing vision loss from macular edema [6, 7]. The gene discussed is VEGFA; the disease is diabetes mellitus.